JP2018528162A5 - - Google Patents

Download PDF

Info

Publication number
JP2018528162A5
JP2018528162A5 JP2017568292A JP2017568292A JP2018528162A5 JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5 JP 2017568292 A JP2017568292 A JP 2017568292A JP 2017568292 A JP2017568292 A JP 2017568292A JP 2018528162 A5 JP2018528162 A5 JP 2018528162A5
Authority
JP
Japan
Prior art keywords
carbon atoms
optionally substituted
branched
alkyl
alkynyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017568292A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018528162A (ja
JP6843080B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/039796 external-priority patent/WO2017004025A1/en
Publication of JP2018528162A publication Critical patent/JP2018528162A/ja
Publication of JP2018528162A5 publication Critical patent/JP2018528162A5/ja
Application granted granted Critical
Publication of JP6843080B2 publication Critical patent/JP6843080B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017568292A 2015-06-29 2016-06-28 システイン改変抗体の複合体 Active JP6843080B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562186254P 2015-06-29 2015-06-29
US62/186,254 2015-06-29
US201662338245P 2016-05-18 2016-05-18
US62/338,245 2016-05-18
PCT/US2016/039796 WO2017004025A1 (en) 2015-06-29 2016-06-28 Conjugates of cysteine engineered antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021025322A Division JP2021088581A (ja) 2015-06-29 2021-02-19 システイン改変抗体の複合体

Publications (3)

Publication Number Publication Date
JP2018528162A JP2018528162A (ja) 2018-09-27
JP2018528162A5 true JP2018528162A5 (cg-RX-API-DMAC10.html) 2019-08-08
JP6843080B2 JP6843080B2 (ja) 2021-03-17

Family

ID=56409216

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2017568292A Active JP6843080B2 (ja) 2015-06-29 2016-06-28 システイン改変抗体の複合体
JP2021025322A Pending JP2021088581A (ja) 2015-06-29 2021-02-19 システイン改変抗体の複合体
JP2022129205A Active JP7441281B2 (ja) 2015-06-29 2022-08-15 システイン改変抗体の複合体
JP2024021646A Pending JP2024067036A (ja) 2015-06-29 2024-02-16 システイン改変抗体の複合体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021025322A Pending JP2021088581A (ja) 2015-06-29 2021-02-19 システイン改変抗体の複合体
JP2022129205A Active JP7441281B2 (ja) 2015-06-29 2022-08-15 システイン改変抗体の複合体
JP2024021646A Pending JP2024067036A (ja) 2015-06-29 2024-02-16 システイン改変抗体の複合体

Country Status (24)

Country Link
US (3) US10898579B2 (cg-RX-API-DMAC10.html)
EP (2) EP3313845B1 (cg-RX-API-DMAC10.html)
JP (4) JP6843080B2 (cg-RX-API-DMAC10.html)
KR (1) KR102793098B1 (cg-RX-API-DMAC10.html)
CN (2) CN107708810B (cg-RX-API-DMAC10.html)
AR (1) AR106013A1 (cg-RX-API-DMAC10.html)
AU (2) AU2016285929B2 (cg-RX-API-DMAC10.html)
CA (1) CA2988806C (cg-RX-API-DMAC10.html)
CY (1) CY1123606T1 (cg-RX-API-DMAC10.html)
DK (1) DK3313845T3 (cg-RX-API-DMAC10.html)
ES (1) ES2832527T3 (cg-RX-API-DMAC10.html)
HR (1) HRP20201790T1 (cg-RX-API-DMAC10.html)
HU (1) HUE052616T2 (cg-RX-API-DMAC10.html)
LT (1) LT3313845T (cg-RX-API-DMAC10.html)
MA (1) MA42250B1 (cg-RX-API-DMAC10.html)
MD (1) MD3313845T2 (cg-RX-API-DMAC10.html)
PL (1) PL3313845T3 (cg-RX-API-DMAC10.html)
PT (1) PT3313845T (cg-RX-API-DMAC10.html)
RS (1) RS61050B1 (cg-RX-API-DMAC10.html)
RU (1) RU2733740C2 (cg-RX-API-DMAC10.html)
SI (1) SI3313845T1 (cg-RX-API-DMAC10.html)
SM (1) SMT202000614T1 (cg-RX-API-DMAC10.html)
TW (2) TWI740833B (cg-RX-API-DMAC10.html)
WO (1) WO2017004025A1 (cg-RX-API-DMAC10.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
RS65120B1 (sr) * 2015-11-25 2024-02-29 Immunogen Inc Farmaceutske formulacije i postupci za njihovu upotrebu
EP3544983A2 (en) 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives
MD3558391T2 (ro) 2016-12-23 2022-05-31 Immunogen Inc Imunoconjugate care țintesc ADAM9 și procedee de utilizare a acestora
WO2018183494A1 (en) 2017-03-31 2018-10-04 Immunogen, Inc. Cd19-targeting antibody-drug conjugates
TWI826393B (zh) * 2017-09-22 2023-12-21 美商免疫遺傳股份有限公司 使用陽離子交換層析法分離三輕鏈抗體
CA3177215C (en) 2017-09-29 2026-06-09 Daiichi Sankyo Company, Limited Antibody-pyrrolobenzodiazepine derivative conjugate
TWI897855B (zh) 2018-10-26 2025-09-21 美商免疫遺傳股份有限公司 E p C A M 抗體、可活化抗體及免疫偶聯物以及其用途
WO2020092533A2 (en) 2018-10-30 2020-05-07 Immunogen, Inc. Methods of treatment using anti-cd123 immunoconjugates
AU2019381628A1 (en) * 2018-11-12 2021-05-27 Immunogen, Inc. Methods of preparing cytotoxic benzodiazepine derivatives
CN112996792B (zh) * 2018-11-12 2024-04-26 伊缪诺金公司 制备细胞毒性苯并二氮杂卓衍生物的方法
CA3119956A1 (en) 2018-11-14 2020-05-22 Daiichi Sankyo Company, Limited Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
AU2020240310A1 (en) * 2019-03-21 2021-10-07 Immunogen, Inc. Methods of preparing cell-binding agent-drug conjugates
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
BR112021017616A2 (pt) 2019-03-25 2021-11-09 Daiichi Sankyo Co Ltd Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina
EP3949988A4 (en) 2019-03-27 2022-11-16 Daiichi Sankyo Company, Limited COMBINATION OF AN ANTIBODY-PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE AND A PARP INHIBITOR
JP7585231B2 (ja) 2019-04-29 2024-11-18 イミュノジェン, インコーポレイテッド 抗cd123免疫複合体を含む治療的組み合わせ
EP4209506A4 (en) 2020-09-02 2024-10-09 Daiichi Sankyo Company, Limited NEW ENDO-N-ACETYL GLUCOSAMINIDASE
CN117425501A (zh) 2021-01-13 2024-01-19 纪念斯隆凯特琳癌症中心 抗体-吡咯并苯二氮䓬衍生物缀合物
WO2023100829A1 (ja) 2021-11-30 2023-06-08 第一三共株式会社 プロテアーゼ分解性マスク抗体
AU2023218678A1 (en) 2022-02-09 2024-08-01 Daiichi Sankyo Company, Limited Environmentally responsive masked antibody and use thereof
IL315341A (en) 2022-03-02 2024-10-01 Daiichi Sankyo Co Ltd METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
US20250345449A1 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of blastic plasmacytoid cell neoplasm
WO2025235924A2 (en) 2024-05-10 2025-11-13 Immunogen, Inc. Anti-cd123 immunoconjugates for the treatment of acute myeloid leukemia
TW202606758A (zh) 2024-05-31 2026-02-16 美商維泰克斯製藥公司 抗cd74抗體組合物及方法
USD1125537S1 (en) * 2024-08-26 2026-05-05 Astrazeneca Ab Medical injector

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
EP0563475B1 (en) 1992-03-25 2000-05-31 Immunogen Inc Cell binding agent conjugates of derivatives of CC-1065
GB9422383D0 (en) * 1994-11-05 1995-01-04 Wellcome Found Antibodies
HK1049997B (en) 1999-11-24 2007-02-23 Immunogen, Inc. Cytotoxic agents comprising taxanes and their therapeutic use
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
US6716821B2 (en) 2001-12-21 2004-04-06 Immunogen Inc. Cytotoxic agents bearing a reactive polyethylene glycol moiety, cytotoxic conjugates comprising polyethylene glycol linking groups, and methods of making and using the same
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
EP1534674A4 (en) 2002-08-02 2007-11-28 Immunogen Inc CYTOTOXIC AGENTS CONTAINING NEW, EFFECTIVE TAXANES AND THEIR THERAPEUTIC USE
EP1542723B1 (en) 2002-08-16 2011-02-23 ImmunoGen, Inc. Cross-linkers with high reactivity and solubility and their use in the preparation of conjugates for targeted delivery of small molecule drugs
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
CN101239190B (zh) * 2003-01-27 2013-09-25 恩多塞特公司 维生素受体结合递药缀合物
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US7276497B2 (en) 2003-05-20 2007-10-02 Immunogen Inc. Cytotoxic agents comprising new maytansinoids
US7837980B2 (en) 2004-03-02 2010-11-23 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
NZ551180A (en) 2004-06-01 2009-10-30 Genentech Inc Antibody drug conjugates and methods
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
US20080305044A1 (en) 2004-11-29 2008-12-11 Seattle Genetics, Inc. Engineered Antibodies and Immunoconjugates
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
PT2032606E (pt) 2006-05-30 2014-02-05 Genentech Inc Anticorpos e imunoconjugados e respetivas utilizações
EP2626372B1 (en) 2007-03-29 2018-03-21 Genmab A/S Bispecific antibodies and methods for production thereof
NZ588884A (en) 2008-04-30 2013-05-31 Immunogen Inc Cross-linkers and their uses
UA108598C2 (xx) 2008-04-30 2015-05-25 Високоефективні кон'югати та гідрофільні зшиваючі агенти (лінкери)
CA3014224C (en) * 2009-02-05 2022-05-24 Immunogen, Inc. Condensed benzodiazepine-indoline derivatives and processes to prepare said derivatives
US8431416B2 (en) * 2009-04-01 2013-04-30 Becton, Dickinson And Company Reactive heterocycle-substituted 7-hydroxycoumarins and their conjugates
BRPI1015234A2 (en) 2009-06-22 2018-02-20 Medimmune Llc fc regions designed for site specific conjugation.
WO2011092838A1 (ja) 2010-01-29 2011-08-04 株式会社フォーサイド・ドット・コム コンテンツ共有システム、およびコンテンツ共有方法
CN105777907B (zh) * 2010-02-24 2020-03-17 伊缪诺金公司 叶酸受体1抗体与免疫缀合物以及其用途
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
PT2560993T (pt) 2010-04-20 2024-09-16 Genmab As Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas
CA2815277A1 (en) 2010-10-29 2012-05-03 Immunogen, Inc. Novel egfr-binding molecules and immunoconjugates thereof
JP5828902B2 (ja) 2010-10-29 2015-12-09 イミュノジェン, インコーポレイテッド 非拮抗性egfr結合分子およびその免疫複合体
SI2675480T1 (sl) * 2011-02-15 2019-05-31 Immunogen, Inc. Metode priprave konjugatov
WO2013177481A1 (en) * 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
HK1219423A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
WO2014134457A2 (en) 2013-02-28 2014-09-04 Immunogen, Inc. Conjugates comprising cell-binding agents and cytotoxic agents
HK1219422A1 (zh) 2013-02-28 2017-04-07 Immunogen, Inc. 包含细胞结合剂及细胞毒素剂的轭合物
ES2719584T3 (es) * 2014-04-11 2019-07-11 Medimmune Llc Compuestos conjugados que comprenden anticuerpos modificados por ingeniería genética con cisteína
KR20170020868A (ko) * 2014-06-20 2017-02-24 바이오얼라이언스 씨.브이. 항-폴레이트 수용체 알파 (fra) 항체-약물 컨쥬게이트 및 그것의 사용 방법
CA2952834A1 (en) * 2014-06-20 2015-12-23 Abgenomics International Inc. Her2 antibody-drug conjugates
WO2015196089A1 (en) * 2014-06-20 2015-12-23 Bioalliance C.V. Anti-cd22 antibody-drug conjugates and methods of using thereof
MA40539A (fr) * 2014-09-02 2016-03-10 Immunogen Inc Procédés de formulation de compositions de conjugués anticorps-médicaments
MA41645A (fr) 2015-03-04 2018-01-09 Abbvie Stemcentrx Llc Anticorps issus de génie génétique spécifiques au site et méthodes d'utilisation
SMT202100092T1 (it) 2015-06-29 2021-03-15 Immunogen Inc Anticorpi anti-cd123 e loro coniugati e derivati
EP3544983A2 (en) * 2016-11-23 2019-10-02 Immunogen, Inc. Selective sulfonation of benzodiazepine derivatives

Similar Documents

Publication Publication Date Title
RU2017144859A (ru) Конъюгаты сконструированных антител с цистеиновыми заменами
CN119306732B (zh) 生物活性物偶联物及其制备方法和用途
EP3964237B1 (en) Biologically active molecules, conjugates thereof, and therapeutic uses
EP3327027B1 (en) Cytotoxic peptides and antibody drug conjugates thereof
AU2022204711B9 (en) Peptidic linkers and cryptophycin conjugates, useful in therapy, and their preparation
JP2017529837A5 (cg-RX-API-DMAC10.html)
AU2018368520B2 (en) Ligand-drug-conjugates as substrates for selective cleavage by the exopeptidase activity of Cathepsin B
EP2790731A2 (de) Fgfr-binder-wirkstoff konjugate und ihre verwendung
EP3501546A2 (de) Cystein-wirkstoff konjugate und ihre verwendung
US20090105200A1 (en) Combination therapy
EP3408271A1 (en) Maytansinoid derivatives, conjugates thereof, and methods of use
JP2018016629A (ja) 固形腫瘍を治療するためのfap活性化プロテアソーム阻害剤
JP2017514905A5 (cg-RX-API-DMAC10.html)
TW202515620A (zh) 抗體-藥物偶聯物靶向治療前列腺癌和其他腫瘤
EP4183799A1 (en) Method for producing antibody-drug conjugate
US20180185498A1 (en) Prodrugs activated by caspase
CA3003085A1 (en) Cryptophycin compounds and conjugates, their preparation and their therapeutic use
JP2016510730A5 (cg-RX-API-DMAC10.html)
HK40085405A (en) Method for producing antibody-drug conjugate
Rieth et al. Cytoprotection in Chemo–and Radiotherapy with Amifostine (Ethyol): A New Strategy in Oncology
EA045708B1 (ru) Новые пептидные линкеры и конъюгаты на основе криптофицина, их получение и их терапевтическое применение
HK40066743A (en) Biologically active molecules, conjugates thereof, and therapeutic uses